News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

ICR Logo
Breast cancer patients with gene fault at increased risk of disease returning

03/07/13

Women with breast cancer who have inherited a damaged version of a gene called CHEK2 are at increased risk of dying from the disease, a major new study reports.
ICR Logo
The promise of immunotherapy - and bridging the funding gap

03/07/13

The ICR's Professor Paul Workman, has featured in a BBC Newsnight investigation into promising new cancer treatment approaches including immunotherapy – and the financial stumbling blocks that could stop these advances reaching patients.
ICR Logo
New breast cancer test will help women avoid unnecessary chemotherapy

01/07/13

A new genetic test for breast cancer will help identify those women who should be considered for chemo, and those who can avoid it, say ICR researchers.
ICR Logo
From caterpillars to cancer

26/06/13

How researchers are beginning to exploit the mysterious phenomenon of epigenetics
ICR Logo
Reaction to the Comprehensive Spending Review

26/06/13

The ICR's Chief Executive, Professor Alan Ashworth, comments on the potential impact of today's budget announcements on scientific research in the UK.
ICR Logo
New national guidelines on breast cancer screening

25/06/13

Read our response to today’s launch by NICE of new national guidelines on familial breast cancer, which expand access to BRCA testing.
ICR Logo
First stage study finds potential new drugs for childhood cancer

20/06/13

Scientists at the ICR have made a step towards new targeted drugs for children with the highest-risk form of a childhood cancer called neuroblastoma.
ICR Logo
Video: New targeted drugs for childhood cancer pass first hurdle

19/06/13

Scientists at The Institute of Cancer Research, London, have made huge progress towards testing two new targeted drugs for children with the highest-risk form of a childhood cancer called neuroblastoma. Pre-clinical study results show that the growth of cancerous neuroblastoma cells with an overactive MYCN gene were disrupted after treatment with two Aurora kinase inhibitors called MLN8054 and MLN8237. Dr Louis Chesler, who co-led of the study, tells us more about the difficulties in treating neuroblastoma, and how these new drugs may be used to treat children.
ICR Logo
Testing micro-RNAs could aid myeloma diagnosis

19/06/13

Tiny pieces of genetic material called micro-RNAs – miRNAs for short – could help improve diagnosis in people with myeloma, a study at The Institute of Cancer Research, London has shown.
ICR Logo
New research sheds light on treatment-resistant breast cancers

19/06/13

ICR scientists have identified a new way of treating breast cancers that could overcome their resistance to a vitally important class of cancer drugs.
ICR Logo
Virus combines with radiotherapy to kill cancer cells

18/06/13

A virus strain used to vaccinate people against smallpox could significantly improve treatment of aggressive skin cancer, an ICR study reports.
ICR Logo
‘Next generation’ cancer drug shows promise in early trial

11/06/13

A new potential cancer drug has shown promising results in an early stage clinical trial. The drug, called AUY922, could help lead to a new way to treat a wide range of cancers including breast and lung cancer

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.